🪞MIRROR RCT🪞 💊MTX ⬆️ response of Pegloticase in resistant gout pts (60% vs PBO 30.8%) 🦶Tophus resolution wk 52 >24 (cont. benefit💪🏻) 🧪⬇️ drug Ab with MTX ✅ No new IRs Abst#0001 #ACR22 @RheumNow #plenary https://t.co/8lPKQ0VGqC

Excellent start to the first plenary session! MIRROR study - MTX coadministration with pegloticase for gout treatment - doubling of efficacy and 7x decrease in infusion reactions - less anti-PEG abs @RheumNow #ACR22 Abs#0001 https://t.co/V1HIYypmpO

2022 IIM-assoc'd CA screening key takeaways Most common CA: lung, ovarian, colorectal, lymphoma, breast, & naso-pharyngeal High risk: DM, +anti-TIF1 gamma, +antiNXP2, >40 at IIM dx, severe/active dz, cutaneous necrosis, dysphagia Abs 0002 #ACR22 @RheumNow https://t.co/BhF1jJa8Oz https://t.co/oLVTLG34ck

• Cancer Screening Recommendations for Patients with Idiopathic Inflammatory Myop…

So good to be back in the plenary hall. It’s on #ACR22 @RheumNow https://t.co/0ppQy5CA3m

Best Overall! by Dr. Lauren Harper #ACR22 Image Competition @rheumnow https://t.co/D3bKJTx6ir

Keynote lecture from Abraham Varghese at #ACR22 @RheumNow Opening Session Physicians and Patients ◦ Physical examination is meaningful and cannot be replaced by technology ◦ Don’t treat the EHR, treat the patient ◦ Acknowledge how much goes into patient care by our nurses https://t.co/piV0O8O7Hw

@MayoClinic data for bari in relapsing GCA caused waves at #ACR21 Spanish data looking at real-world practice: slightly longer, slower GCA, but equally encouraging outcomes waiting for SELECT-GCA with interest! @EBRheum ABST0464 #ACR22 @RheumNow https://t.co/pVRPXAohhc https://t.co/FgNNfPSWk3

• https://twitter.com/drdavidliew/status/1457688108338606083

Ab0349 #ACR22 BEL vs AZA ifn risks in non-renal SLE BEL: lower risk of severe ifn (HR 0.81) and hospitalization for ifn (HR 0.73) through 5 yrs Challenge to interpret data as 56% of patients were on glucocorticoids and other anti-rheumatic meds @RheumNow https://t.co/a0tNFn5Wqr

⬆️ correlation between BASDAI + ASQoL in 🙋‍♂️ vs 🙋‍♀️ What does this mean? ❓low disease activity in 🙋‍♀️ resulting in more marked ⬇️ in QoL❓ OR ❓Is there a need for gender stratified tools of disease activity❓ Abst#0406 #ACR22 @RheumNow @Sineadm15

A #myositis discussion will not be complete without a slide on myositis antibodies - @JuliePaikMD Great review slide for trainees! #ACR22 @Rheumnow #RheumTwitter @rheumarhyme @PhRheumaJr @doktora_ging https://t.co/e6cB344vH8

MIRROR results showed 12-month safety/efficacy support MTX co-therapy w/ pegloticase. No IRs after 6mo of tx and increased resolution of tophi at wk 52. I use MTX in my gout pts on Pegloticase. Are you #rheumtwitter? Abs 0001 #ACR22 @RheumNow https://t.co/FLwOmAYrS4

• 12-month Findings of the Randomized, Double-Blind, Placebo-Controlled, Multicen…

🔸DM pts who are anti-TIF-1 Ab+ have higher risk of malignancy 🔸Ovarian cancer - most common Really important to do cancer screening in #dermatomyositis #ACR22 @RheumNow https://t.co/jErqcR0Gyr

Study of IV tocilizumab for GCA that led to FDA approval of intravenous TCZ this year (2/2022) -one of Dr. C Langford's pick for #YearinReview @rheumnow #ACR22 https://t.co/luxDDluddM

• Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia R…

Is it the medication or behaviour that increases mortality? #SLICC grp showed in #SLE severe non-adherence to #HCQ in Yr 1 of #lupus = 3 poor outcomes -more 1 flares, 2 damage, 3 5yr-death. Surrogate of other poor health behaviours and/or HCQ? abst#0343 #ACR22 #ACRBest @RheumNow https://t.co/tTRdyti0sf